SillaJen’s Novel HCC Therapy Set For Phase III
This article was originally published in PharmAsia News
SillaJen, a private South Korean clinical-stage biotherapeutics company focused on the development of immunotherapies for cancer, is set to begin a global Phase III clinical trial with its candidate Pexa-Vec later this year, following an agreement with the U.S. FDA on a Special Protocol Assessment (SPA).
You may also be interested in...
Among the Korean firms presenting at J.P. Morgan, Hanmi laid out its strategy for obesity and other core pipeline assets, Celltrion focused on its expanding biosimilar pipeline and China plans and LG Chem unveiled new R&D progress.
BeiGene licenses antibody therapeutics for Castleman’s disease and high-risk neuroblastoma.
After a year full of disappointing and unexpected events, the South Korean pharma sector is hoping for a turnaround in 2020, with expected biosimilar launches in global markets, progress in drug pipelines, large IPOs and implementation of a new law on cutting-edge biologics.